Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified "HTLV-1-associated lichenoid dermatitis" as a skin condition in HTLV-1-infected individuals, characterized by reactive eruptions associated with increased immunity toward infected CD4+ T cells.

This study explored peripheral blood immune dysregulation in alopecia areata through single-cell analyses, identifying systemic changes linked to disease severity and key signaling roles for monocytes, NK cells, and memory T cells, suggesting potential therapeutic targets.

This study found that treatment with EGFR inhibitors or mitogen-activated kinase inhibitors may compromise the immune privilege of human scalp hair follicles, suggesting new directions for managing drug-induced folliculitis.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This study found that topical application of Astragalus membranaceus extract induced hair regrowth and reduced immune response markers in mice with natural hair loss.

This study systematically compared pediatric and adult Cushing's disease patients, revealing more severe and earlier-onset symptoms in males, and distinct gender-specific clinical manifestations.

This study reported that the most reliable way to differentiate alopecia areata from androgenic alopecia is by detecting intrafollicular CD3 and CD8 cell density, with CD3 being the most specific and sensitive marker.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

This study suggests that IL-17 may play a more significant role than IFN-γ in the pathogenesis of chronic alopecia areata, with increasing severity linked to Th17 lymphocytes and cytotoxic T lymphocyte infiltration.

This research suggests that innate lymphoid cells type 1 (ILC1) may contribute to the development of alopecia areata, alongside CD8+ T cells, by disrupting hair follicle immune privilege and promoting features of the disease.

In this study, increased production of CXCL10 was associated with the infiltration of Th1 and Tc1 cells in acute alopecia areata, suggesting a possible new target for treatment.

A patient's skin rash did not affect the area where a previous viral rash was healing, suggesting a rare immune response.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

This study found that for thyroid cancer patients who underwent radical mastectomy, the combination of CAF regimen and fufangbanmao capsule improved short-term clinical efficacy, enhanced immune function, reduced drug toxicity, and positively impacted quality of life compared to the CAF regimen alone.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This animal study observed that treatment with the S1PR modulator NXC736 significantly reduced lesion area and CD8+ T cell infiltration in mice with alopecia areata, suggesting its potential as a promising therapy for the condition.

In this study, the elimination of NG2+ hair follicle stem cells during the anagen phase was associated with an aggravated sensitization phase of allergic contact dermatitis, suggesting their immunosuppressive role.

This article discusses diffuse alopecia areata, highlighting its autoimmune characteristics, more intense inflammation, and challenges in diagnosis, but presents no new clinical findings.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

This case report documents the development of vitiligo-like lesions in a patient with autoimmune thyroiditis following the use of topical squaric acid dibutylester for alopecia.

This review discusses non-motor symptoms in autoimmune myasthenia gravis and associated thymomas, highlighting abnormal T-cell clones as a contributing factor, but reports no new clinical results.

This article describes a rare case of alopecia with both scarring and non-scarring features, combining histologic signs of central centrifugal cicatricial alopecia with select immunologic features of alopecia areata.

IL-27 may help prevent hair loss by creating immune-suppressing cells.

This study identified key genes linked to immune cells and potential therapeutic compounds for alopecia areata by evaluating upregulated genes from patient datasets, highlighting T and NK cell involvement in hair follicle attack and suggesting drug candidates through molecular docking and dynamics simulations.

This study developed and analyzed a mathematical model for alopecia areata involving interactions among immune cells and cytokines, establishing conditions under which hairless patches can become stable and pervasive, particularly with certain biological rate levels and chemotactic sensitivities.

In this case report, mogamulizumab treatment for Sézary syndrome was associated with rashes and alopecia in a patient, highlighting the potential for immune-mediated side effects and suggesting that such adverse effects might indicate a favorable prognosis, though further studies are needed.